Do you want to read an article? Please log in or register.
Population pharmacokinetic modeling and simulation of fremanezumab in healthy subjects and patients with migraine
Migraine and Headache
Related content
Migraine and Headache
Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach
Cephalalgia
Cohen-Barak O, Radivojevic A, Jones A, Fiedler-Kelly J, Gillespie M, Brennan M, Gutman D, Rasamoelisolo M, Hallak H, Loupe P, Kessler Y, Ning X, Levi M, Ahn AH, Rabinovich-Guilatt L
doi: 10.1177/03331024211007789
Migraine and Headache
Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine
Cephalalgia.
Brandes JL, Kudrow D, Yeung PP, Sakai F, Aycardi E, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y
doi: 10.1177/0333102419885905.
RECOMMENDED
Migraine and Headache
Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses
★ 2
Recommended by
Prof. Dr Christian Kamm, Faculty Member
doi: 10.1111/head.13845.
Migraine and Headache
Impact of Depression and Anxiety Symptoms on Patient-Reported Outcomes in Patients With Migraine: Results From the American Registry for Migraine Research (ARMR)
Headache.
Pearl TA, Dumkrieger G, Chong CD, Dodick DW, Schwedt TJ
doi: 10.1111/head.13911.
Migraine and Headache
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
Headache
Lipton RB, Cohen JM, Bibeau K, Galic M, Seminerio MJ, Ramirez Campos V, Halker Singh RB, Ailani J
doi: 10.1111/head.13997
Migraine and Headache
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study
Headache
Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC
doi: 10.1111/head.14196
RECOMMENDED
Migraine and Headache
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Cephalalgia.
Brandes JL, Diener HC, Dolezil D, Freeman MC, McAllister PJ, Winner P, Klatt J, Cheng S, Zhang F, Wen S, Ritter S, Lenz RA, Mikol DD
doi: 10.1177/0333102419894559.
Migraine and HeadacheStroke
Migraine and risk of stroke: a national population-based twin study
Brain.
Lantz M, Sieurin J, Sjölander A, Waldenlind E, Sjöstrand C, Wirdefeldt K
doi: 10.1093/brain/awx223.
Migraine and HeadacheAnxiety and Depression
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial
JAMA.
Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E